Evaluation of ADC Mapping as an Early Predictor for Tumor Response to Chemotherapy in Recurrent Glioma Treated with Bevacizumab/Irinotecan: Proof of Principle;Evaluation des ADC-Mappings als Prädiktor für ein Ansprechen von Glioblastomrezidiven auf eine Therapie mit Avastin

RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren

Volumn 182, Issue 10, 2010, Pages 868-872

  Ringelstein, A ^a   Turowski, B ^a   Gizewski, E R ^b   Schroeteler, J ^a   Rapp, M ^a   Saleh, A ^a   Lanzman, R S ^a   Mathys, C ^a   Sabel, M ^a   Modder U ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

brain; experimental study; MR diffusion perfusion

Indexed keywords

BEVACIZUMAB; IRINOTECAN; WATER; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CONTRAST MEDIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GADOLINIUM; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

APPARENT DIFFUSION COEFFICIENT; ARTICLE; BRAIN MAPPING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CLINICAL ARTICLE; DIFFUSION; EXTRACELLULAR SPACE; FEASIBILITY STUDY; GLIOMA; HUMAN; IMAGE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROOF OF CONCEPT; TREATMENT RESPONSE; BRAIN; BRAIN TUMOR; DIFFUSION WEIGHTED IMAGING; DRUG ANTAGONISM; FEMALE; FOLLOW UP; GLIOBLASTOMA; IMAGE PROCESSING; MALE; METHODOLOGY; PATHOLOGY; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING; TUMOR RECURRENCE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN; BRAIN NEOPLASMS; CAMPTOTHECIN; CONTRAST MEDIA; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FOLLOW-UP STUDIES; GADOLINIUM; GLIOBLASTOMA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; MALE; NEOPLASM RECURRENCE, LOCAL; SENSITIVITY AND SPECIFICITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77958453301     PISSN: 14389029     EISSN: 14389010     Source Type: Journal    
DOI: 10.1055/s-0029-1245570     Document Type: Article

References (26)

1. Stupp R., Mason W. P., Bent M. J. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med: 2005; 352 987 996
2. Macdonald D. R., Cascino T. L., Schold J. r SC et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol: 1990; 8 1277 1280
3. Vredenburgh J. J., Desjardins A. van den, Herndon J. E 2nd et al. Phase II trial of Bevacizumab and Irinotecan recurrent malignant glioma. Curr Neurol Neurosci Rep: 2008; 8 233 234
4. Bokstein F., Shpigel S., Blumenthal D. T. Treatment with Bevacizumab and Irinotecan for recurrent high-grade glial tumours. Cancer: 2008; 112 2267 2273
5. Iwamoto F. M., Abrey L. E., Beal K. et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology: 2009; 73 1200 1206
6. Sathornsumetee S., Cao Y., Marcello J. E. et al. Tumour angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with Bevacizumab and Irinotecan. J Clin Oncol: 2008; 26 271 278
7. Murakami R., Sugahara T., Nakamura H. et al. Malignant supratentorial astrocytoma treated with postoperative radiation therapy: prognostic value of pretreatment quantitative diffusion-weighted MR imaging. Radiology: 2007; 243 493 499
8. Sankar T., Caramanos Z., Assina R. et al. Prospective serial proton MR spectroscopic assessment of response to tamoxifen for recurrent malignant glioma. J Neurooncol: 2008; 90 63 76
9. Chen W., Delaloye S., Silverman D. H. et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with (18F) fluorothymidine positron emission tomography: a pilot study. J Clin Oncol: 2007; 25 4714 4721
10. Padhani A. R., Liu G., Mu-Koh D. et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia: 2009; 11 102 125
11. Moffat B. A., Chenevert T. L., Lawrence T. S. et al. Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response. PNAS: 2005; 102 5524 5529
12. Naganawa S., Sato K., Katagiri T. et al. Regional ADC values of the normal brain: differences due to age, gender, and laterality. Eur Radiol: 2003; 13 6 11
13. Hamstra D. A., Galbán C. J., Meyer C. R. et al. Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol: 2008; 26 3387 3394
14. Norden A. D., Drappatz J., Wen Y. Antiangiogenetic therapy in malignant glioma. Curr Opin Oncol: 2008; 7 1152 1160
15. Plate K., Breier G., Weich H. et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human glioma in vivo. Nature: 1992; 359 845 848
16. Friedman H. S., Prados M. D., Wen P. Y. et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol: 2009; 27 4733 4740
17. Rafii S. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy. Nat Rev Cancer: 2002; 2 826 835
18. Pope W. B., Kim H. J., Huo J. et al. Recurrent Glioblastoma Multiforme: ADC Histogram Analysis Predicts response to Bevacizumab Treatment. Radiology: 2009; 252 182 189
19. Minamikawa S., Kono K., Nakayama K. et al. Glucocorticoid treatment of brain tumour patients: changes of apparent diffusion coefficient values measured by MR diffusion imaging. Neuroradiology: 2004; 46 805 811
20. Boxerman J. L., Schmainda K. M., Weisskoff R. M. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. Am J Neuroradiol: 2006; 27 859 867
21. Sawlani R. N., Raizer J., Horowitz S. W. et al. Glioblastoma: A Method for Predicting Response to Antiangiogenic Chemotherapy by Using MR Perfusion Imaging-Pilot Study. Radiology: 2010; 255 622 628
22. Tofts P. S., Kermode A. G. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med: 1991; 17 357 367
23. Parker G. J., Tofts P. S. Pharmacokinetic analysis of neoplasms using contrast-enhanced dynamic magnetic resonance imaging. Top Magn Reson Imaging: 1999; 10 130 142
24. Roberts C., Issa B., Stone A. et al. Comparative Study into the Robustness of Compartmental Modeling and Model-Free Analysis in DCE-MRI Studies. J Magn Reson Imaging: 2006; 23 554 563
25. Evelhoch J. L. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging: 1999; 10 254 259
26. Jackson A., Jayson G. C., Li K. L. et al. Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma. Br J Radiol: 2003; 76 153 162